Avid and Halozyme expand supply relationship

Related tags Contract

Avid Bioservices and Halozyme Therapeutics have expanded their relationship, adding manufacturing agreements and designating the CMO as a preferred supplier.

The new deal amends and expands commercial supply agreements for human hyaluronidase (rHuPH20) which is used in two of Halozyme’s products. Furthermore, the companies have entered into a new commercial supply agreement for additional rHuPH20 products.

Avid has also been designated as a preferred supplier of future Halozyme products which require the contract manufacturing organisation’s (CMO) process development and biomanufacturing capabilities and expertise.

"Expanding our commercial supply relationship with Avid is a testament to the strong relationship we have developed over the past five years​", added Jonathan Lim, Halozyme's president and CEO.

Related topics Contract Manufacturing & Logistics

Related news

Follow us


View more